Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.
Adult T cell leukemia/lymphoma (ATL) is a poor prognosis T cell malignancy. In order to improve the outcome, we employed allogeneic stem cell transplantation (allo-SCT) for ATL in 10 patients, nine of whom were from HLA-identical siblings and one from an unrelated donor. Conditioning regimens varied among the patients except that all received total body irradiation. The patients tolerated the regimens well with mild, if any toxicity, and engraftment occurred in all cases. Median leukemia-free survival after allo-SCT was 17.5+ months (range 3.7-34.4+). Six of the 10 patients developed acute GVHD (one case each with grade I, III or IV, and three cases with grade II) and three patients developed extensive chronic GVHD. Four patients died after allo-SCT during the study period from either acute GVHD (grade IV), pneumonitis, gastrointestinal bleeding or renal insufficiency. Two of the 10 cases with no symptoms of GVHD relapsed with clinical ATL. These results strongly suggest that allo-SCT may improve the survival in ATL if a controlled degree of GVHD develops.
Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan.
A
A
Utsunomiya
Y
Y
Miyazaki
Y
Y
Takatsuka
S
S
Hanada
K
K
Uozumi
S
S
Yashiki
M
M
Tara
F
F
Kawano
Y
Y
Saburi
H
H
Kikuchi
M
M
Hara
H
H
Sao
Y
Y
Morishima
Y
Y
Kodera
S
S
Sonoda
M
M
Tomonaga
D000328:Adult; D002423:Cause of Death; D004279:DNA, Viral / Q000097:blood; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality / Q000592:standards*; D015368:Human T-lymphotropic virus 1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D007564:Japan; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000601:surgery* / Q000821:virology; D016399:Lymphoma, T-Cell / Q000601:surgery* / Q000821:virology; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods / Q000592:standards; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D004279:DNA, Viral